semaglutide shortage Drug prescribed for type 2 diabetes in short supply over weight-loss hype fda semaglutide shortage status january

Saxenda may require long-term use

Dyspepsia, characterized by upper abdominal discomfort, early satiety, or postprandial fullness, may affect a similar proportion of patients and can contribute to reduced caloric intake and weight loss, though it may also impact quality of life if severe or persistent

We have observed a variety of violations including: GLP-1 drugs being advertised in jurisdictions where it is not permitted GLP-1 drugs being offered for sale without a prescription Scammers offering GLP-1 drugs but not shipping anything Compounding pharmacies claiming that their GLP-1 drugs are FDA-approved Additionally, because compounded versions of these drugs have not been FDA-approved, there is increased risk of problems with safety and efficacy of these products

- Treatment cycles vary depending on individual needs and goals, but most patients see significant results in 6-12 months